Linked Life Data

19403994

Source:http://linkedlifedata.com/resource/pubmed/id/19403994

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
1
pubmed:dateCreated
2009-5-15
pubmed:abstractText
The effect of zonisamide, an antiepileptic agent with anti-parkinsonian effects, was studied on dopamine neurons of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-treated C57 mice and common marmosets. Groups of mice (n = 8 - 9) were treated with: MPTP (15 mg/kg every 2 h x4); MPTP plus zonisamide (40 mg/kg administered 1 h before each MPTP dose); MPTP plus selegiline (2 mg/kg administered 1 h before the first MPTP dose); zonisamide (40 mg/kg x4); and saline controls. Groups of common marmosets (n = 4 - 6) were treated with: MPTP (2.5 mg/kg every 24 h x3); MPTP plus zonisamide (40 mg/kg administered 1 h before each MPTP dose); MPTP plus selegiline (2 mg/kg administered 1 h before the first MPTP dose); and saline controls. Brain dopamine and its metabolites were determined by HPLC. Dopamine content decreased in the striatum of MPTP-treated mice and monkeys. Co-administration of selegiline inhibited the effect of MPTP and dopamine contents were similar to those of the controls. Co-administration of zonisamide did not inhibit the effect of MPTP on dopamine content, but increased striatal dopamine turnover of animals treated with MPTP plus zonisamide more than in those treated with MPTP alone. MPTP treatment caused a compensatory increase of dopamine turnover in the striatum by remaining neurons. Zonisamide may help dopaminergic neurons by increasing striatal dopamine turnover following MPTP treatment.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
May
pubmed:issn
1347-8613
pubmed:author
pubmed:issnType
Print
pubmed:volume
110
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
64-8
pubmed:meshHeading
pubmed-meshheading:19403994-1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine, pubmed-meshheading:19403994-3,4-Dihydroxyphenylacetic Acid, pubmed-meshheading:19403994-Animals, pubmed-meshheading:19403994-Anticonvulsants, pubmed-meshheading:19403994-Biogenic Amines, pubmed-meshheading:19403994-Brain Chemistry, pubmed-meshheading:19403994-Callithrix, pubmed-meshheading:19403994-Dopamine, pubmed-meshheading:19403994-Dopamine Agents, pubmed-meshheading:19403994-Dyskinesia, Drug-Induced, pubmed-meshheading:19403994-Homovanillic Acid, pubmed-meshheading:19403994-Isoxazoles, pubmed-meshheading:19403994-Male, pubmed-meshheading:19403994-Mice, pubmed-meshheading:19403994-Mice, Inbred C57BL, pubmed-meshheading:19403994-Monoamine Oxidase, pubmed-meshheading:19403994-Monoamine Oxidase Inhibitors, pubmed-meshheading:19403994-Neostriatum, pubmed-meshheading:19403994-Neurons, pubmed-meshheading:19403994-Selegiline
pubmed:year
2009
pubmed:articleTitle
Zonisamide increases dopamine turnover in the striatum of mice and common marmosets treated with MPTP.
pubmed:affiliation
Department of Therapeutic Medicine, Ehime University Graduate School of Medicine, Japan.
pubmed:publicationType
Journal Article, Research Support, Non-U.S. Gov't